KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Average (2016 - 2025)

Teva Pharmaceutical Industries' Equity Average history spans 17 years, with the latest figure at $7.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 28.88% year-over-year to $7.6 billion, compared with a TTM value of $7.6 billion through Dec 2025, up 28.88%, and an annual FY2025 reading of $6.6 billion, down 1.6% over the prior year.
  • Equity Average for Q4 2025 was $7.6 billion at Teva Pharmaceutical Industries, up from $7.0 billion in the prior quarter.
  • The five-year high for Equity Average was $11.4 billion in Q3 2021, with the low at $5.8 billion in Q1 2025.
  • Average Equity Average over 5 years is $8.5 billion, with a median of $7.9 billion recorded in 2023.
  • Year-over-year, Equity Average dropped 25.68% in 2021 and then rose 28.88% in 2025.
  • Tracing TEVA's Equity Average over 5 years: stood at $11.3 billion in 2021, then dropped by 20.23% to $9.1 billion in 2022, then decreased by 14.31% to $7.8 billion in 2023, then fell by 24.17% to $5.9 billion in 2024, then rose by 28.88% to $7.6 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Equity Average are $7.6 billion (Q4 2025), $7.0 billion (Q3 2025), and $6.6 billion (Q2 2025).